Cancer of Unknown Primary Site Clinical Trial
Official title:
Real World Study of Diagnosis and First-line Treatment Among Patients With Cancer of Unknown Primary in China
| NCT number | NCT04952103 |
| Other study ID # | Fudan-CUP-003 |
| Secondary ID | |
| Status | Recruiting |
| Phase | |
| First received | |
| Last updated | |
| Start date | June 18, 2021 |
| Est. completion date | June 18, 2024 |
| Verified date | June 2021 |
| Source | Fudan University |
| Contact | Xin Liu |
| Phone | 13761503356 |
| jeanettexin[@]hotmail.com | |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
This study is a prospective, real world study.The objective is to observe the diagnosis and first-line treatment of Chinese patients with cancer of unknown primary, and collect the clinicopathological characteristics, treatment outcomes, survival and other data of the patients.
| Status | Recruiting |
| Enrollment | 200 |
| Est. completion date | June 18, 2024 |
| Est. primary completion date | June 18, 2023 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | N/A and older |
| Eligibility | Inclusion Criteria: - Had a diagnosis of cancer of unknown primary (CUP) after a standard evaluation . - Prepared to receive first-line therapy for CUP Exclusion Criteria: - Patients who had previously received systemic therapy for CUP - Previous history of other cancers, except cervix cancer or basal cell carcinoma of the skin that has been cured - The investigator considered that there were contraindications to treatment or were not appropriate to participate in this study |
| Country | Name | City | State |
|---|---|---|---|
| China | Fudan University Shanghai Cencer Center | Shanghai | Shanghai |
| Lead Sponsor | Collaborator |
|---|---|
| Fudan University |
China,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Progression-free survival (PFS) | 8 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03278600 -
Tissue-of-origin Directing Therapy in Patients With Cancer of Unknown Primary
|
Phase 3 | |
| Recruiting |
NCT04504604 -
TCF-001 TRACK (Target Rare Cancer Knowledge) Study
|
N/A | |
| Completed |
NCT03053466 -
APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT04750109 -
Carcinoma of Unknown Primary (CUP): A Comparison Across Tissue and Liquid Biomarkers
|
||
| Recruiting |
NCT04969835 -
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
|
Phase 1 | |
| Active, not recruiting |
NCT03498521 -
A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
|
Phase 2 | |
| Completed |
NCT01845337 -
Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine
|
Phase 2 | |
| Recruiting |
NCT05263700 -
FAPI-CUP- Evaluating FAPI as a Novel Radiopharmaceutical for Cancer of Unknown Primary
|
N/A | |
| Active, not recruiting |
NCT03752333 -
Trial of Pembrolizumab in Cancer of Unknown Primary
|
Phase 2 | |
| Completed |
NCT05841966 -
Surgeon-performed Intraoperative Transoral Ultrasound for Cancer of Unknown Primary
|
N/A | |
| Recruiting |
NCT04131621 -
Nivolumab/Ipilimumab in Second Line CUP-syndrome
|
Phase 2 | |
| Recruiting |
NCT04459273 -
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
|
Phase 1 | |
| Active, not recruiting |
NCT05024968 -
Sintilimab in Cancer of Unknown Primary
|
Phase 2 |